WASHINGTON (September 18, 2024) — The Association for Accessible Medicines and its Biosimilars Council today responded to current discussions over potential savings on GLP-1 class medications.
As the 2024 U.S. Generic & Biosimilar Medicines Savings Report shows—and as we celebrate the 40th anniversary of the Hatch-Waxman Act—it’s more critical than ever for policymakers to protect generic and biosimilar competition.
WASHINGTON (September 5, 2024) — The Association for Accessible Medicines, the trade association representing generic and biosimilar manufacturers, today released its 2024 U.S. Generic & Biosimilar Medicines Savings Report. AAM’s annual savings report reveals that the use of Food and Drug Administration (FDA) approved generic and biosimilar medicines created $445 billion in savings in 2023 for patients, employers, taxpayers, and the healthcare system—over $3 trillion in the last decade.
WASHINGTON (May 30, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, today submitted comments to the U.S.
WASHINGTON (April 17, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, commented on an analysis released yesterday by Avalere showing that Medicare plans increase patient costs for generic medicines by moving thos
Last month, as part of its Fiscal Year 2025 budget, the Biden Administration proposed a new initiative under the Medicare Part D program to require all Part D plans to offer a standard list of generic drugs with a maximum copayment of $2 per 30-day supply.
Generic Pharmaceutical Trade Group Steps in to Protect Patient Access to Affordable Generic Drugs
WASHINGTON, DC (JULY 5, 2023) – The Association for Accessible Medicines (AAM), the trade association representing America’s manufacturers of generic and biosimilar medicines, today filed a lawsuit against Minnesota Attorney General Keith Ellison, requesting that the federal district court in Minnesota enjoin the Attorney General from enforcing the price-control provisions of Senate File 2744.
Each year, we look forward to hosting our members, friends, colleagues and partners for Access!, AAM’s annual meeting. Held in Orlando, Florida, this year’s conference was unique in that we also hosted the 25th Annual Meeting of the International Generic and Biosimilar Medicines Association (IGBA) in the same location, a dual experience that helped to strengthen global cooperation in our shared effort to expand patient access to more affordable generic and biosimilar medicines.
Entrepreneur and founder of the Mark Cuban Cost Plus Drug Company, PBC, Mark Cuban, sat down with our new Board Chair Christine Baeder, SVP, COO for US Generics at Teva Pharmaceuticals, to discuss his efforts to reduce #drugprices and increase competition in the drug market. #Access2023 #drugprices #patientaccess
